Limited Competition: Biospecimen Banks to Support NCI-Clinical Trials Network (NCTN) (U24)
This Funding Opportunity Announcement (FOA) solicits applications from institutions/organizations to establish Biospecimen Banks for the NCI National Clinical Trials Network (NCTN; https://research.usc.edu/nci-national-clinical-trials-network-nctn-program/). The NCTN Biospecimen Banks will be responsible for collecting, storing, and distributing well-annotated human specimens from patients with cancer who are participating in NCI-funded Phase III and large Phase II clinical treatment trials. The goal is to support NCTN with the state-of the-art biospecimen banking infrastructure and operations including maintenance of up-to-date specimen inventory. The NCTN Banks will distribute to qualified investigators the biospecimens linked to high-quality clinical data (including treatment and outcome information) that are critical for developing and validating biomarkers for cancer diagnosis, prognosis and prediction of responses to therapy. The NCTN Banks will work in collaboration with NCTN Groups and Group Statistical and Data Management Centers to ensure effective operation. One of the NCTN banks will be also expected to provide banking services for the NCI Experimental Therapeutics Clinical Trials Network (ETCTN; http://ctep.cancer.gov/initiativesPrograms/etctn.htm/). ETCTN collects biospecimens from cancer patients treated on NCI Phase I and small Phase II clinical trials).
General information about this opportunity
Last Known Status
Deleted 09/15/2014 (Archived.)
Program Number
RFA-CA-14-501
Federal Agency/Office
Agency: Department of Health and Human Services
Office: National Institutes of Health
Type(s) of Assistance Offered
Cooperative Agreement
Number of Awards Available
5
Who is eligible to apply/benefit from this assistance?
Applicant Eligibility
Other Eligible Applicants include the following: Eligibility is limited to an institution/entity that is operating the physical infrastructure of one or more existing Group Banks of human specimens from Phase II and III cancer clinical treatment trials funded under RFA-CA-09-504 (irrespective of whether the actual award under RFA-CA-09-504 was made to this institution/entity or to another institution/entity under the former NCI-sponsored Clinical Trials Cooperative Group Program structure). The eligible institutions may configure themselves at their discretion in terms of location of the biospecimen banking infrastructure (maintaining current or moving to a new location) and/or the selection of the institution/entity submitting the application (which can also be a foundation if it is a recipient of the NCTN Operations Center award under RFA-CA-12-010) for one of the NCTN Groups, as long as a group of institutions applying together is affiliated for biospecimen banking with one and only one NCTN Group funded under RFA-CA-12-010. Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
What is the process for applying and being award this assistance?
Deadlines
08/15/2014
Other Assistance Considerations
Formula and Matching Requirements
This program does not have cost sharing or matching requirements.
Who do I contact about this opportunity?
Headquarters Office
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Website Address
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-14-501.html
E-mail Address
FBOWebmaster@OD.NIH.GOV
Financial Information
Obligations
$11,750,000.00
Range and Average of Financial Assistance
Awards up to $11,750,000.00
